EUVIMEDEUVIMED entdecken
Crossref

Tigecycline displays bactericidal activity against multidrug-resistant Neisseria gonorrhoeae and enhances clearance from a mouse infection model

Xia Sun, Wenyan Lu, Haoyu Ge, Yuling Qin, Dailin Yuan, Xu'ai Lin, Yuefeng Rao, Stijn van der Veen iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Xia Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of …. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Tigecycline, Anti-Bacterial Agents, Gonorrhea. Die Arbeit nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The global emergence of ceftriaxone-resistant Neisseria gonorrhoeae threatens current first-line treatment and necessitates alternative therapeutic options. Tigecycline, a last-line glycylcycline antibiotic approved for complicated infections, was evaluated for repurposing against N. gonorrhoeae through in vitro and in vivo activity studies.

Methods

Antimicrobial susceptibility testing was performed for 616 clinical isolates (2011–2024) from Hangzhou, China, and bactericidal activity was determined in time-kill assays. A mouse vaginal tract infection model was used to evaluate in vivo tigecycline activity. Chequerboard assays were performed to assess interactions between tigecycline and ceftriaxone.

Results

Tigecycline demonstrated potent activity (MIC50: 0.125 mg/L; MIC90: 0.25 mg/L), including against tetracycline-resistant (tetracycline MIC50: 2 mg/L; MIC90: 64 mg/L) and high-level ceftriaxone-resistant (ceftriaxone MIC50: 0.03 mg/L; MIC90: 0.125 mg/L) strains. Time-kill assays (2 strains) revealed concentration-dependent bactericidal activity, with 4×MIC achieving ≥105-fold killing. In the mouse vaginal tract infection model, high-dose tigecycline (25 mg/kg) significantly enhanced bacterial clearance, eliminating infection within 3–6 days compared to 8–12 days in vehicle controls, and substantially reduced bacterial burden. Chequerboard assays against 21 isolates (10 ceftriaxone-susceptible, 11 ceftriaxone-resistant) demonstrated indifferent interactions between tigecycline and ceftriaxone (fractional inhibitory concentration indices 1.03–2.56), indicating no antagonism.

Conclusions

These findings establish that tigecycline exhibits potent, rapid bactericidal activity against N. gonorrhoeae, including against high-level ceftriaxone-resistant strains, with robust in vivo efficacy. They support further investigation of tigecycline as a potential repurposing candidate for multidrug-resistant gonorrhoea, although its clinical role remains to be defined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeTigecyclineAnti-Bacterial AgentsGonorrheaDrug Resistance, Multiple, BacterialAnimalsMiceFemaleMicrobial Sensitivity TestsDisease Models, AnimalCeftriaxoneHumansThird Generation CephalosporinsChina

Substanzen

TigecyclineAnti-Bacterial AgentsCeftriaxoneThird Generation Cephalosporins

Autor:innen und Institutionen

  • Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, China.
  • Zhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Stijn van der Veen

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Sun, X., Lu, W., Ge, H., Qin, Y., Yuan, D., Lin, X., Rao, Y., & van der Veen, S. (2026). Tigecycline displays bactericidal activity against multidrug-resistant Neisseria gonorrhoeae and enhances clearance from a mouse infection model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag337

Vancouver

Sun X, Lu W, Ge H, Qin Y, Yuan D, Lin X, et al. Tigecycline displays bactericidal activity against multidrug-resistant Neisseria gonorrhoeae and enhances clearance from a mouse infection model. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag337

BibTeX
@article{Sun2026,
  author = {Sun, Xia and Lu, Wenyan and Ge, Haoyu and Qin, Yuling and Yuan, Dailin and Lin, Xu'ai and Rao, Yuefeng and van der Veen, Stijn},
  title = {Tigecycline displays bactericidal activity against multidrug-resistant Neisseria gonorrhoeae and enhances clearance from a mouse infection model},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag337}
}
Kostenlos starten →